Chinese Bioscience Association 18 Annual Conference ... · 2 CBA Chinese Bioscience Association Shih-Chen Chang Ph.D. 2015 CBA President The Chinese Bioscience Association (CBA),

Date : October 10, 2015, 8:30am - 4:30pmLocation: Crowne Plaza, Foster City, California

Chinese Bioscience Association 18th Annual Conference灣區華人生物科技協會第十八届年會

CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA BA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA C A CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CB CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA BA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA C A CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CB CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA BA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA C A CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CB CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA BA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA C A CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CB CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA BA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA CBA C

Future of the Life Science Industry - Innovation and Opportunities

生命科學行業的未來 - 創新與機遇

Chinese Bioscience Association 18th Annual Conference灣區華人生物科技協會第十八届年會Chinese Bioscience Association 18th Annual Conference灣區華人生物科技協會第十八届年會

CBA CHINESEBIOSCIENCEASSOCIATION

Our Mission

To Promote NetworkingServing the Life Sciences professionals’ interests in the Bay Area and facilitate networking between professionals locally and globally

To Promote AwarenessEnhancing public awareness of the progress and development of the Life Science industry

To Update and Educate Facilitating a better understanding of key trends in Life Sciences as well as encouraging scientific innovation to address unmet medical needs

To Forge CollaborationForging active collaborations with other organizations in areas of mutual interests

MEMBERSHIP & BENEFITS

• Network for success• Connect with other professionals

and share technical interests• Keep skills and knowledge current

and relevant • Create new partnerships• Free or discounted admission to

seminars and workshops• Free admission to Annual Summer

Picnic• Discounted admission to Annual

Conference• Members’ children can apply for

the Ho Family Scholarship• Online career resources including

job posting• Eligibility to vote or become a

board member

VOLUNTEERING

• Create a positive impact in community

• Share passion, talents and expertise with others

• Hone leadership and management skills

• Develop interpersonal skills• Balance lifestyle

CBA Chinese Bioscience Association


www.cbasf.org Email: [email protected]

Editor-in-Chief: Anthony Liou

EDITORIALSenior Editor:Caesar Ho

Layout Editor:Anthony Liou

Advertising Editor:Susan Liang Jing Folsom

ART and PHOTOGRAPHYCover/Layout Designer:

Anthony Liou

Photographers:Mark ChenCindy Liu

Logo Designer:Candy Tang

Published for Annual Conference, Education

and Communication

Copyright © 2015 CBAAll rights reserved

Printer: JASK Digital Printing

& Copy Solutions

CBA Chinese Bioscience Association 1

CONTENTS

2 President’s Message

3 Conference Chair’s Message

4 Conference Agenda 6 Invited Speakers Information SESSION I: Precision Medicine, Next Generation Sequencing, Real World Data and Neuroscience Ho Family Scholarship Award LUNCH SESSION: Mobile Health Technology SESSION II: Immuno-Oncology, Intellectual Property, Stem Cells and Biosimilar SESSION III: Leadership in Biotech

20 CBA Organization and Key Events State CBA organization, mission and connections. Introduce the 2015 board, advisors and events.

24 Navigating Life Sciences investments and Entrepreneurship between US and the Far East

26 Singapore-Sichuan Hi-Tech Innovation (SSCIP) Dinner

27 CBA Annual Summer Picnic

28 CBA History Message from one of CBA’s Founders. Timeline of CBA leadership.

30 Sponsors Information CBA appreciates the generous support from our sponsors.


2 CBA Chinese Bioscience Association

Shih-Chen Chang Ph.D.2015 CBA President

The Chinese Bioscience Association (CBA), a bi-lingual and non-profit organization, has been established for more than 15 years in the Bay Area. Each year, CBA holds scientific conferences and workshops highlighting emerging trends and cutting-edge knowledge advancement in the life sciences associated topics, and has become one of the key platforms in promoting education, networking, and community building for life science professionals among students, post-docs, scientists, entrepreneurs, business community as well as academic institutes.

In 2015, CBA has organized several exciting activities providing avenues for CBA members and friends to socialize and network. With our close tie to the Asia Pacific regions as well as the Bay Area, one of CBA’s missions is to bridge the investments, industries and talents gaps between US and Asia. To this end, we have organized a well received workshop entitled “Modern Seafarers: Navigating Life Sciences Investments & between US and the Far East”, showcasing esteemed speakers from US, India, China and Taiwan sharing invaluable insights as well as current underlying challenges and opportunities in life science business investments in these regions. In addition, we also hosted The Singapore-Sichuan Hi-Tech Innovation Park delegation, and facilited meetings with company executives and entrepreneurs in the Bay Area, as well as provide opportunities to showcase the biomedical sciences innovation park jointly developed by Singapore and Sichuan, located in Chengdu, China. CBA will continue our support in the launch of the Ho Family Scholarship. And this year, we are pleased to announce that there will be two scholarships in lieu of the single award last year. Finally, we have another great turnout of over 150 at our annual summer picnic, providing an excellent opportunity for CBA members and their families and friends to socialize and network, amidst good music and great food.

The theme of this year’s conference is “Future of the Life Science Industry – Innovations and Opportunities”. The Bay Area is not only a fertile ground for developing novel bioscience technology in the United States, it also continues to house one of the world’s largest and most diverse biotech communities. To remain competitive, the Life Science industry must continue to develop and maintain innovative disease pipelines. It must also cut cost by streamlining clinical trials and optimize operational efficiency as well as forming win-win partnerships bringing about next generation technologies and access to the global market. In our 2015 annual conference, several aspects within the process from drug discovery to clinical use will be showcased, highlighting brilliant innovations and new opportunities that lie within.

Finally, I would like to thank all our sponsors, speakers, and conference/event participants. Your support is the key motivator that enables CBA to grow and improve. Last but not least, as a volunteer-based organization, I would like to personally thank the tremendous support from CBA board members, advisors, and volunteers. Without their dedication and tireless efforts, we would not have accomplished all that we have achieved thus far!

Sincerely,

President’s Message

Shih-Chen Chang Ph.D.



It is with great pleasure that I welcome you to the 2015 CBA Annual Conference. The theme of the conference is “Future of the Life Science Industry − Innovation and Opportunities”. We will explore many cutting-edge topics across the life scienc-es field through multiple sessions in this conference.

In Session I, Dr. Peter Yu will provide his insights and perspectives regarding emerging opportunities and challenges in the development and introduction of new cancer therapeutics. Dr. Radoje Drmanac will update the latest developments and applications of next generation sequencing. Following a short networking break, Dr. Jacqueline Law will discuss how data collected outside of traditional clinical trial settings can impact the drug development paradigm. Next, Dr. Lennart Mucke will outline the latest mechanistic insights on Alzheimer’s disease and the potential to translate to improved treatments. At the end of Session I, we will present the Ho Family Scholarship Awards.

During the Lunch Session, Ms. Mary Vincent will introduce the latest mobile health technology and its impact on healthcare.

In Session II, Dr. Tim Hoey will present the current development of first-in-class biologic agents that block key cancer stem cell pathways. This is followed by Dr. Janet Xiao, who will highlight the legal challenges in life science and the strate-gies to secure valuable patents. After another short networking break, Dr. Hiromitsu Nakauchi will share the latest discoveries in stem cell research – generation of a functional organ from pluripotent stem cells. In the following segment, Dr. Scott Liu will discuss the current landscape and future prospects of biosimilar development in China.

We will conclude our meeting with an interesting panel discussion on leadership in the biotech industry. Our esteemed panelists are Drs. Janet Xiao, Xi Zhao-Wilson, Licen Xu, and Ruhong Jiang.

In summary, we hope the annual conference will provide a good platform for insight-ful discussions and stimulate new ideas. It will also provide excellent networking opportunities and enhance career development for academia and industry attendees.

Thank you for your continuing support. I hope you will enjoy the conference.

Sincerely,

Conference Chair’s Message

Kai Zheng Ph.D.2015 Conference Chair

Kai Zheng Ph.D.


CBA 18th ANNUAL CONFERENCE

8:30 - 9:00 am

9:00 - 9:05 am

9:05 - 9:10 am

SESSION I 9:10 - 9:50 am

9:50 - 10:20 am

10:20 - 10:35 am

10:35 - 11:05 am

11:05 - 11:35 am

11:35 - 11:45 am

11:45 - 12:15 pm

Registration, Networking and Exhibitions

Welcome and Opening RemarksShih-Chen Chang, Ph.D., CBA President 2015

Conference IntroductionKai Zheng, Ph.D., CBA Conference Chair 2015

Moderator: Shih-Chen Chang, Ph.D., CBA President 2015Oncology: The Near and Far HorizonPeter Yu, M.D., FACP, FASCO, ASCO President (2014-2015), Director of Cancer Research, Palo Alto Medical Foundation

Advanced Massively Parallel Sequencing: Improving Disease Prevention and TreatmentRadoje (Rade) Drmanac, Ph.D., Chief Scientific Officer, Complete Genomics

Networking and Exhibitions

Real World Data – Changing Drug Development ParadigmJacqueline Law, Ph.D., Senior Director, Genentech

Moderator: Cheni Kwok, Ph.D., CLP, Managing Partner, Linear Dreams Developing Better Treatments for Dementing Disorders: The Long and Short of ItLennart Mucke, M.D., Director, Gladstone Institute of Neurological Disease

Ho Family Scholarship AwardCaesar Ho


AGENDA October 10, 2015, 9:00 am -- 4:30pmCrowne Plaza, Foster City, California




Moderator: Michelle Chen, Ph.D., Executive Director of Business Development & Strategic Alliances, NanoString How will Mobile Health Technologies Change the Way We Live? A Global Trekker’s PerspectiveMary Vincent, Co-Founder of LifetimeMD

Moderator: Sydney Chen, Ph.D., Partner, Kiang Consulting Development of New Therapeutic Agents Targeting Key Cancer Stem Cell PathwaysTim Hoey, Ph.D., Senior Vice President, OncoMed Pharmaceuticals

Navigating the “Wild West” of Intellectual Property – Challenges of Patent Protection on Hot TopicsJanet Xiao, Ph.D., J.D., Partner, Morrison & Foerster


Moderator: Lin Sun-Hoffman J.D., President, Sun-Hoffman Consulting“Organs, not Cells” - Generation of Functional Organs from iPS cells via Interspecies Blastocyst ComplementationHiromitsu Nakauchi, M.D., Ph.D., Professor of Genetics, Stanford University School of Medicine

Development of Biosimilars in China: Current Situations and Future TrendsScott Liu, Ph.D., President and CEO, Henlius Biotech


Moderator: Michelle Chen, Ph.D., Executive Director of Business Development & Strategic Alliances, NanoString Panel Discussion - Leadership in Biotech: How to Break the Glass Ceiling while Maintain Career and Life BalancePanelists: Janet Xiao, Ph.D., J.D., Partner, Morrison & Foerster Xi Zhao-Wilson, Ph.D., CEO, BioMarker Pharma Licen Xu, Ph.D., Senior Director, Thermo Fisher Scientific Ruhong Jiang, Ph.D., CEO, Applied StemCell

Closing RemarksKai Zheng, Ph.D., Conference Chair 2015

LUNCH SESSION

12:15 - 1:00 pm

SESSION II 1:00 - 1:30 pm

1:30 - 2:00 pm

2:00 - 2:15 pm

2:15 - 2:45 pm

2:45 - 3:15 pm

3:15 - 3:30 pm

SESSION III

3:30 - 4:25 pm

4:25 - 4:30 pm



Keyn

ote Sp

eaker

ABSTRACTThe development and introduction of new cancer therapeutics into the clinic faces multiple opportunities and challenges. These include new precision medicine and clinical models of cancer, new regulatory approaches and healthcare financing models and a growing need for medical informatics. Gastric cancer will be presented as a model for genotype-phenotype correlations. Emerging concerns regarding the clinical utility of diagnostic laboratory tests, the role of outcomes based measures of success in healthcare reform and the growing concern over affordability and sustainability of care will be discussed.

Peter P. Yu, M.D., FACP, FASCOAmerican Society of Clinical Oncology President

(2014-2015)Director of Cancer Research,

Palo Alto Medical Foundation

Oncology: The Near and Far Horizon



Keyn

ote Sp

eaker

KEYNOTE SPEAKER PROFILEDr. Peter Paul Yu is in clinical practice at the Palo Alto Medical Foundation (PAMF) - Sutter Health system in the San Francisco Bay area. Dr. Yu is the Director of Cancer Research at PAMF and graduated from the combined undergraduate and medical school Program in Medicine at Brown University. His residency was at St. Luke’s Roosevelt Medical Center in New York City where he was Chief Resident. After a fellowship at Mount Sinai Medical Center, Dr. Yu completed a postdoctoral fellowship at Memorial Sloan-Kettering Cancer Center in the laboratory of Dr. John Mendelsohn. He has served as President of the Association of Northern California Oncologists, Chief of Medicine at El Camino Hospital in Mountain View, member of the Board of Directors of pathways Home-care and Hospice and as a member of the Audit Committee of the Alliance for Clinical Trials in Oncology.

Dr. Yu served as President of the American Society of Clinical Oncology (ASCO) 2014-2015, Past ASCO activities have included Board Member, Chair of the Clinical Practice Committee, Chair of HIT Work Group, Chair of Awards Committee, member of the Cancer Research, Integrated Media, Grant Selection, Audit, Nominating, Scientific Program, Education and Quality of Care committees, Chair of the Best of ASCO San Francisco 2005, Chair ASCO EHR Symposium 2009, Annual Meeting Educational Session Chair 2007, 2009, 2010 and 2014, and faculty of the Clinical Trials for the Community Oncology Team Workshop 2005.

Dr. Yu has served as co-chair of the Commission for Certification of Health Information Technology (CCHIT) Oncology work group, co-chair of the AMA-RAND Clinical Decision Support Oncology work group under contract to the Office of the National Coordinator for Health Information Technology, co-chair of the ASCO-NCI CORE informatics project and has participated in several Institute of Medicine health information technology workshops. He is a member of the College of American Pathologists Cancer Biomarker Reporting Committee, the Epic Oncology Steering Board, the Global Alliance for Genomics & Health, and the California Department of Health California Cancer Registry External Advisory Committee.



ABSTRACTHighly massively parallel DNA sequencing using genomic nanoarrays continues to advance our ability to efficiently read DNA. Recent improvements in making patterned DNA Nano-Ball arrays (DNB arrays) provide easy use for all sample types and strong signal for long unbiased reads. These patterned nanoarrays combined with novel powerful cameras allow to generate sequence data with extreme efficiency (e.g. 50x WGS from 30 people per day per instrument) enabling whole genome sequencing (WGS) to be applied as the single comprehensive genetic test. Improved DNB array and fast imaging also enable cost effective desktop sequencers for various research and clinical “omics” application such as NIPT, PGS or targeted cancer tests.When Long Fragment Read (LFR) technology employing co-barcoded reads from long DNA fragments and 100xread coverage is used. Individual human genomes are sequenced at maximal sensitivity, including separate assembly of parental chromosome sequences termed haplotping or phasing. Furthermore, using co-barcoded reads, accurate WGS including detection and phasing of de-novo mutations (~1 error per Gb, ~6 errors per genome) is now achievable from ~10 cells such as in small biopsies obtained from 5-day IVF embryos and potentially fetal cells collected in early pregnancies. In addition, we show that using as few as five CTCs we can accurately find somatic mutations and gene deletions from the founding lineage of the metastatic breast cancer (paper under review). LFR’s co-barcoded reads also allow reference unbiased de-novo assembly of individual genomes for a more comprehensive detection of the currently difficult to call diseases-causing mutations in the complex gene families.

SPEAKER PROFILEDr. Drmanac is one of the founders of the field of Genomics. Currently he serves as Senior VP of BGI (Shenzhen, China) and Director and Chief Scientific Officer (CSO) at Complete Genomics, Inc. (CGI), that he co-founded with Cliff Reid in 2005 to develop technologies for efficient and accurate individual genome sequencing. CGI was acquired by BGI in 2013. Dr. Drmanac invented and led the development of massively parallel DNA sequencing using DNA nanoarrays, ligation-bases DNA sequencing and long fragment read technologies. Earlier, in 1994, he co-founded Hyseq (later Nuvelo and now ARCA), and served as Director until 2001. As SVP of research and CSO, he led Hyseq’s effort to discover and patent thousands of novel genes for its drug development pipeline. Prior to Hyseq, he was a group leader at Argonne National Labs (1991-1994) as part of DOE Human Genome Project. He completed his postdoctoral studies in 1990 at ICRF in London. He received his Ph.D. in Molecular Biology in 1988 at Belgrade University, Serbia, for the conception and pioneering development of the first massively parallel sequencing technology using DNA microarrays. At the same university he received BS (1981) and MS (1985) degrees in Molecular Biology. Since 1987, Dr. Drmanac and his teams received over 50 patents and over $20M in government grants and over $300M in investments for the development of advanced genome sequencing technologies.

Radoje (Rade) Drmanac, Ph.D. Chief Scientific Officer, Complete Genomics

Speakers

Advanced Massively Parallel Sequencing: Improving Disease

Prevention and Treatment



Speakers

Real World Data – Changing Drug Development Paradigm

ABSTRACTIn a broad sense, real world data (RWD) refer to data collected outside of traditional clinical trial settings. The availability and quality of RWD have been improving in recent years. The utility of RWD is also expanding and spans across research and development, regulatory approval and access, as well as medical practice. In the era of personalized medicine, the insights and evidence drawn from RWD have become even more relevant. With an increasing acceptance on using RWD to support decisions, how will the drug development paradigm change?

SPEAKER PROFILEDr. Law is the Global Head of Real World Data Science at Genentech. In this role, Dr. Law leads the Real World Data Science to support the global late stage development, medical affairs and market access in different therapeu-tic areas including oncology, ophthalmology, inflammation, infectious disease, and neuroscience.

Dr. Law joined Roche in 2003 and was the Director of Biometrics at Roche Molecular Systems. In 2005, Dr. Law joined Genentech (a member of the Roche group) and has held positions with increasing responsibilities. Prior to leading the Real World Data Science group, Dr. Law was the Asia Head of Biometrics based in Shanghai from 2011-2014.

Dr. Law received her Ph.D. in Biostatistics from the University of California, Los Angeles.

Jacqueline Law, Ph.D. Senior Director, Genentech



ABSTRACTAlzheimer’s disease and other dementing disorders pose important scientific biomedical and socio-economic problems that require a multi-pronged, interdisciplinary approach. In this lecture, Dr. Mucke will describe molecular and cellular processes thought to trigger or mediate Alzheimer’s disease, as well as synaptic and neural network dysfunctions that may underlie the inexorable cognitive decline and behavioral abnormalities it causes. He will also discuss how some of the latest mechanistic insights might be translated into better treatments for this illness through the development of novel therapeutics or the re-purposing of drugs used for other conditions.

SPEAKER PROFILEDr. Mucke is the founding director of the Gladstone Institute of Neurological Disease and holds joint appointments as the Joseph B. Martin Distinguished Professor of Neuroscience and Professor of Neurology at the University of California, San Francisco. He trained at the Georg-August University and the Max Planck Institute for Biophysical Chemistry in Gottingen, Germany, the Cleveland Clinic, the Massachusetts General Hospital and Harvard Medical School and The Scripps Research Institute.

Dr. Mucke’s research focuses on processes that result in memory loss and other major neurological deficits, with an emphasis on Alzheimer’s disease and related disorders. He has generated informative experimental models of these conditions and used them to identify disease mechanisms and novel strategies to prevent neurological decline.

For this contributions, Dr. Mucke has received the Potamkin Prize from the American Academy of Neurology, the MetLife Foundation Award for Medical Research, the Kalid Iqbal Lifetime Achievement Award and the Zenith Award form the Alzheimer’s Association, the American Pacesetter Award from the ARCS foundation, a MERIT award from the National Institute of Health, and an Award for Excellence in Direct Teaching and Mentoring from the Haile T. Debas Academy of Medical Educators. Dr. Mucke has served on the National Advisory Council on Aging for the NIH and chairs the Senate of the German Center for Neurodegenerative Diseases (DZNE).

Lennart Mucke, M.D. Director, Gladstone Institute of

Neurological Disease

Developing Better Treatments for Dementing Disorders:

The Long and Short of ItSpeakers



Speakers

Ho Family ScholarshipThe Ho Family Scholarship is established in memory of Ellen & Tony C. Ho. It is also intended to continue the family’s tradition of supporting educational endeavors. The family had founded the Chi Yong School in Guangzhou, China and Saigon, Vietnam in the past.

Ellen Ho, a nurse practitioner, worked at Tung Wah Hospital in Hong Kong for over thirty years. She held the position of Head Nurse in the maternity ward before retiring. Tony C. Ho, a chemist by training, worked at Taiwan Sugar in Ping Dong and at San Miguel Brewery in Hong Kong. He joined Merck Sharp & Dohme in 1960, and worked as Plant Manager in Bangkok. Thailand for over 20 years, followed by 10 years at Merck & Co. Headquarters in Rahway, New Jersey.

There will be two Ho Family Scholarships each consist of awards of $500.00 in 2015.

Caesar Ho, the eldest son of Mr. and Mrs. Ho, will serve as the sponsor on the CBA Board. Yvonne Ho & Erika Ho, grand daughters of Mr. and Mrs Ho, will serve as alternate sponsors.

The selected candidates for the Ho Family Scholarships will be announced at the 18th CBA Annual Conference.



Speakers

ABSTRACTIoT Wearable mHealth Technologies are currently impacting Smart City, Smart Home, Data Analytics, and Security decisions made by engineering architects and health professionals. The talk will discuss these technologies, current impacts, and a Telemedicine Heart Failure Use Case.

SPEAKER PROFILEMary Vincent is the Co-Founder and CTO of LifetimeMD a health wearable IoT startup, and was Co-Founder and Head of Product Engineering for a smart fabric wearable computing company, leading global wearable com-puting architecture innovation, integration, testing, quality and technical engagement. Her startup was accepted into the Intel Make it Wearable Semifinals, two Startup Incubators, and she presented in Shenzhen, China, Hard-ware Trek in Taipei Taiwan, Keiretsu Women’s Forum, Draper University, Silicon Valley China Wireless, and was selected as a Delta Tech-crunch Disrupt Innovator.

Ms. Vincent’s background includes work in Sun Microsystems Java Engineering, Data Center Energy Efficiency, and Mobile Health Application development with Stanford and Government Projects in Bhutan and Guatemala. Mary is also an Entrepreneur in Residence at SK Telecom Innopartners where she actively participates in weekly pipeline review meetings of applicant startups to receive up to $1 Million in Funding and lends expertise by being the Technology Subject Matter Expert in Wearables, IoT, mHealth, and Data Center Efficiency. She also provides additional value by recommending and evaluating startups in the decision making process for seed investments. Mary has a unique understanding of the software and hardware worlds and how they work together, and often speaks about the future of wearables and how we can use technology to improve lives.

How will Mobile Health Technologies Change the Way We

Live? A Global Trekker’s Perspective

Mary Vincent Co-Founder and Chief Technology Officer of

LifetimeMD


Speakers

Development of New Therapeutic Agents Targeting Key

Cancer Stem Cell Pathways

ABSTRACTCancer stem cells (or tumor initiating cells) mediate tumor progression, metastasis, and recurrence after therapy. Using our platform of patient-derived xenografts, comprised of approximately 200 tumors, we have developed first-in-class biologic agents that block key CSC pathways including Notch, Wnt and RSPO-LGR. We have developed seven therapeutics currently in clinical testing - anti-DLL4 (demcizumab), anti-Notch2/3 (tarextumab), anti-Notch1 (brontictuzumab), anti-FZD (vantictumab), and Fzd8-Fc (ipacfricept) and anti-DLL4/VEGF. In addition, we have developed a new therapeutic agent, anti-Rspo3. These agents inhibit tumor growth through multiple mechanisms including a reduction of CSC frequency. The presentation will focus on the activity of anti-Rpso3 in colon, lung and ovarian cancers. We have found that anti-Rpso3 reduces tumor growth as a single agent and in combination with chemotherapeutic agents. Anti-Rspo3 treatment inhibits expression of stem cell markers and reduces tumorigenicity in serial transplantation studies. We have observed a strong correlation between Rpso3 expression and sensitivity to treatment, enabling a biomarker-focused strategy for patient selection and clinical development. Anti-Rspo3 (OMP-131R10) entered clinical testing in 2015.

SPEAKER PROFILEDr. Timothy Hoey is Senior Vice President, Cancer Biology at OncoMed Pharmaceuticals. The Cancer Biology group is responsible for testing new drugs targeting cancer stem cells and translational research to discover bio-markers indicative of CSC frequency and patients most likely to respond to OncoMed therapeutic antibodies. Dr. Hoey previously served as Director, Biology Department at Amgen (San Francisco) and was responsible for characterization of oncogenes and development of drugs to target oncogene products. Prior to this he was Director, Biology Department at Tularik, responsible for Cancer and Immunology research.

Prior to joining Tularik, he performed postdoctoral studies on the mechanisms of transcriptional regulation at U.C. Berkeley under Dr. Robert Tijian. Dr. Hoey received his Ph.D. from Columbia University, where he conducted research on regulation of gene expression and embryonic development with Dr. Michael Levine. Dr. Hoey is a co-inventor on several patents and has authored or co-authored over 60 scientific publications.

Tim Hoey, Ph.D.Senior Vice President, Cancer Biology

OncoMed Pharmaceuticals




Speakers

ABSTRACTResearch breakthroughs in the life science industry have opened doors for many exciting areas such as precision medicine, cancer immunotherapy, and mobile health. Intellectual property protection of new discoveries in these areas, however, has been more difficult to obtain than ever. During my talk, I will discuss some of the legal challenges a life science professional would be facing, pitfalls to avoid, and issues to consider in the course of obtaining valuable patent rights in these areas. I will also discuss unique considerations for patent rights arising from US/China collaborations.

SPEAKER PROFILEDr. Janet Xiao is a partner in Morrison & Foerster’s Life Science Group residing in the Palo Alto office. She primarily represents clients in the biotechnology and pharmaceutical industries in their world-wide patent procurement, patent portfolio management, and strategic planning. Dr. Xiao advises biopharmaceutical companies and research institutions on patent matters relating to various technologies including antibody therapeutics, nanomedicine, personalized medicine, drug delivery systems, drug screening platforms, diagnostics, and nutraceuticals.

Dr. Xiao also works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, as well as marketing and manufacturing clearances for biopharmaceutical products. She is among the very few IP attorneys who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issue unique to China and Chinese clients. In both 2014 and 2015 Dr. Xiao was listed in Chambers Global as a leading IP expert in the U.S. and a leading IP lawyer in China as an expert based abroad.

Navigating the “Wild West” of Intellectual Property – Challenges of Patent Protection on Hot Topics

Janet Xiao, Ph.D., J.D.Partner, Morrison & Foerster LLP


Speakers

“Organs, not Cells” – Generation of Functional Organs from iPS Cells via

Interspecies Blastocyst Complementation

ABSTRACTHematopoietic stem cells (HSCs) have played a flagship role in stem cell biology, providing a number of conceptual ideas and models. Among them is the concept of the “niche”, a special bone-marrow micro-environment that by exchanging cues regulates stem-cell fate (self-renewal, differentiation, hibernation, and proliferation). The concept of the stem-cell niche was further extended to generation of organs. We postulated that an “organ niche” exists in a developing animal and that this niche was empty when development of an organ is genetically disabled. This organ niche, we reasoned, should be compensated developmentally by blastocyst complementation using wild-type pluripotent stem cells. We provided proof of principle of organogenesis from xenogeneic pluripotent stem cells (PSCs). Demonstration of generation of a functional organ from PSCs in mice and pigs is a very important step toward generation of human cells, tissues, and organs from individual patients’ own PSCs in large animals.

SPEAKER PROFILEHiromitsu Nakauchi obtained a M.D. from Yokohama City University School of Medicine and a Ph.D. in immunology from University of Tokyo Graduate School of Medicine. He isolated CD8 genes during his post-doc period at the Laboratory of Prof. Leonard Herzenberg at Stanford University. After returning to Japan, he started working on hematopoietic stem cells in his laboratory at RIKEN. In 1994, he became Professor of Immunology at the University of Tsukuba where he demonstrated that a single hematopoietic stem cell could reconstitute the entire hematopoietic system, a definitive experimental proof for the “stemness”. Since April 2002, he has been a Professor of Stem Cell Therapy in the Institute of Medical Science at The University of Tokyo (IMSUT). In 2008, he was appointed Director of newly established Center for Stem Cell Biology and Regenerative Medicine at IMSUT. Just recently, he returned to Stanford University as a faculty to continue his stem cell research at the Institute of Stem Cell Biology and Regenerative Medicine. Goals of his work are to translate discoveries in basic research into practical medical applications.

Hiromitsu Nakauchi, M.D., Ph.D.Professor of Genetics,

Stanford University School of Medicine




Speakers

ABSTRACTThe current focus of biologics R&D in China is still predominantly on biosimilars. Upon the publication of the Guidelines for Biosimilar Development and Evaluation by the CDE of CFDA in March, 2015, the biologics industry of China has a renewed opportunity to enter the mainstream international market through elevated and harmonized quality standards. The presentation will touch upon the key topics/issues facing the biosimilar industry in China, including: 1. The analysis and projection of the mAb-based biosimilar market in China; 2. The biosimilar development and competition landscape in China; 3. Key features and implications of the CDE Guidelines for Biosimilar Development and Evaluation; 4. Future trends of the industry: financial, regulatory, manufacturing and globalization aspects; 5. Example of Shanghai Henlius: Strategic thinking and positioning.

SPEAKER PROFILEDr. Scott Liu, graduated from Purdue University, Department of Biology, was a postdoctoral fellow at Stanford University, and later pursued iMBA courses at Syracuse University. As the Founder, President and CEO of Henlius Biopharmaceuticals, Inc. and Shanghai Henlius Biotech Co., Ltd., he takes overall responsibility for strategic planning and implementation, as well as operation management. Benefiting from Scott’s vision in achieving quality at reasonable cost, Shanghai Henlius Biotech Co., Ltd. has adopted advanced technologies in mAb development and manufacturing, and, in doing so, significantly reduced the manufacturing costs while maintaining the quality of the products.

Before founding his own companies, Scott held key technical and/or leadership positions in several leading biopharmaceutical companies, including Amgen, Bristol-Myers Squibb, United Biomedicals (UBI), Tanox and Maxygen. He was the Director of Quality Analytical Labs of Amgen-Fremont, and took responsibility for quality control operations for late-phase development and cGMP commercial manufacturing of Vectibix. Prior to Amgen, Scott held the post of Associate Director of Biologics QC in BMS-Syracuse, he was in charge of QC operations for late phase development and commercial manufacturing of Orencia.

Dr. Liu has 20 years’ experience of biopharmaceutical development, manufacturing, drug administration and quality management , and he won the title of “ 1000 Planning Expert of Shanghai “ in 2013.

Development of Biosimilars in China: Current Situations and

Future Trends

Scott Liu, Ph.D.President and CEO, Henlius Biotech


Speakers

Leadership in Biotech: How to Break the Glass Ceiling while

Maintain Career and Life Balance (Panel Speaker)

SPEAKER PROFILEDr. Xi Zhao-Wilson is the founding CEO of BioMarker Pharmaceuticals Inc. She currently serves as the Chairwoman of the Board of Directors of BioMarker. BioMarker is developing a new class of therapeutics to prevent and treat chronic diseases and to slow down the rate of aging. The company has launched a consumer genomic product under her leadership. She has initiated active collaborations between academia and industrial partners, including several institutes of the Chinese Academy of Sciences and other prestigious universities in China, in the US and in foreign countries.

Dr. Zhao-Wilson received her Ph.D. in Cellular Biology and Developmental Biology from the Ohio State University, and her M.S. in molecular genetics and cell biology from the Institute of Cell Biology, Chinese Academy of Sciences. She received her MBA from Fisher School of Business and her executive management training from MIT Sloan School of Management.

Dr. Zhao-Wilson has over twenty years of experience as a senior executive of start-up, early stage and established companies in the biotech and biomedical industry. Prior to BioMarker, she was a corporate development executive at Aviron, a biopharmaceutical company that was acquired by AstraZeneca. She was a founder and CEO of InCell, a biotech company in stem cell research and its medical application. Dr. Zhao-Wilson was a Research Scientist at Stanford University.

Dr. Zhao-Wilson is a Professor at the Chinese Academy of Preventative Medicine, and a Professor at Xi’An JiaoTong University, China. She has been awarded multiple U.S. and foreign patents and has published numerous peer-reviewed articles, book chapters, and reviews. She has been awarded research funding through SBIR Grant from the U.S. Department of Health and Human Services, funding from private organizations, and an award from the Katherine McCormick Fund. She has also lectured extensively at numerous universities in the U.S., China and in European countries. She currently serves as a member of ILC board of MIIS, Graduate School of Middlebury University.

Xi Zhao-Wilson, Ph.D., M.B.A.Founding CEO, BioMarker Pharmaceuticals




Speakers

SPEAKER PROFILEDr. Xu has a diverse background in the life sciences, currently serving as a Senior Director for Life Science Group in Thermo Fisher Scientific, where she manages AB Sequencing business, including instrument portfolio, consumables and applications. Prior positions include managing Next Generation Sequencing platform and bioinformatics product portfolio. She had spent several years in biopharmaceutical drug discovery and bioinformatics product development.

She earned her bachelor’s degree in Electrical Engineering and Master’s Degree of Biophysics from Tsinghua University, Beijing, China. She obtained her Ph.D of Molecular Biology at University of Zurich, Switzerland.

Outside work, she enjoys working in the garden, playing sports, movie going and spending fun time with her children, family and friends.



Licen Xu, Ph.D.Senior Director, Thermo Fisher Scientific


Speakers



SPEAKER PROFILEDr. Jiang is co-founder and CEO of Applied StemCell, Inc. - A global leading company in stem cell and precise genome editing. He has held a variety of technical and managerial roles with increasing responsibilities in several biotechnology/biopharmaceutical companies.

Before starting Applied StemCell, Dr. Jiang was general manager of MicuRx(Shanghai) Pharmaceutical Inc., a California-based biopharmaceutical company where he set up its entire China operation. From 2005 to 2007, Dr. Jiang was head of the Pharmacogenetics Program at Stanford Research Institute International (SRI) where he managed multiple pharmacogenetic and molecular genetics projects with multi-millions of annual budget. Prior to relocating to California, Dr. Jiang was pharmacogenomics consultant at Boehringer Ingelheim Pharmaceuticals and served as senior scientist, then director of project management at Genaissance Pharmaceuticals from 2000 to 2004 where he played an important role in biomarker discovery, pharmacogenetics and clinical bioinformatics, diagnostic product development, alliance management and business development.

Dr. Jiang graduated from Fudan University with a B.S. degree in biology, and received M.S. degree in reproductive biology from China Agricultural University and a Ph.D. degree in Genetics from Oklahoma State University in 1997. From there Ruhong went to Baylor College of Medicine where he furthered his education as a postdoctoral fellow in Dr. Douglas Burrin’s lab. Dr. Jiang has authored and co-authored more than 40 publications in the fields of human genetics, pharmacogenetics and disease animal models. Ruhong has a deep interest in the science, ethics and societal issues of personalized medicine, regenerative medicine and global health. His demonstrated leadership has led to an established track record of success; especially in the areas of biomarker-based molecular assays or diagnosis, CRO service, and drug research and development.

Ruhong Jiang, Ph.D.Co-Founder and CEO, Applied StemCell



CBA

Org

anizatio

n


MISSIONThe Chinese Bioscience Association (CBA) is a non-profit organization founded in the San Francisco Bay area in 1997. Its mission is to promote education, networking and community building for Life Sciences professionals.

LOCAL PARTICIPATIONSCBA has held hundreds of scientific conferences, seminars and workshops focusing on emerging trends and cutting-edge technologies in the biotech/pharmaceutical industry. CBA currently has hundreds of active members and supports, ranging from company founders, CEOs, business executives, directors, managers, scientists, academic professors, researchers, postdoctoral fellows and students.

GLOBAL CONNECTIONSAs a bi-lingual organization, with strong ties to China, Taiwan, Hong Kong and Singapore, CBA plays a vital role in bridging the industry and cultural gaps between US and Asia. All events, especially the Annual Conferences and educational workshops, are popular with members, and friends. CBA is a volunteer organization generously supported by its members and sponsors.

4Q 2014 to 2015 EVENTS AND ACTIVITIESOctober 4, 2014 17th CBA Annual Conference October 4, 2014 2014 Ho Family Scholarship October 19, 2014 HiRecruit Job Fair (Co-hosted with Taiwan Trade Center, San Francisco)December 6, 2014 US-Taiwan Biomedical Engineering Forum (UTBEF) Conference (Co-hosted with TECO)January 31, 2015 Welcome Lunch for New Board and Advisors June 10, 2015 Modern Seafarer: Navigating Life Sciences Investments and Entrepreneurship between US and the Far East (Co-hosted with EPPIC)June 25, 2015 SSCIP Dinner (Co-hosted with CABS)August 29, 2015 CBA 2015 Annual Summer Picnic at Mitchell Park, Palo Alto



2015 BOARD and ADVISORS President: Shih-Chen Chang Vice Presidents: Kai Zheng, Cheni Kwok Secretary: Mark Chen Treasurer: Katherine Wang Membership: Wenyi Chen Public Relations: Hui-Fang Li e-Commincation: Pengguang Wu Publications: Anthony Liou Sponsorships: Susan Liang, Jing Folsom Alliances: Patrick Yang Scholarship: Caesar Ho Newsletter: Mark Chen Taiwan Liaisons: Frank Lin and Andrew Teng Advisors: Michelle Chen, Lin Sun-Hoffman, Patty Kiang, Cindy Liu, Kelly Liu, Sydney Chen and Cheni Kwok Conference Advisors: Ta-Kai Li and Cheng-Chi Chao Special Thanks to: Betty Kuo, Emily Yan, Jane Wu, Yuan Zhang, Fei Yu, Jenny Chia, Chuan-Tai Yu and Shirley Zhang

MEMBERSHIP PROFILEBased on FieldsBased on Education

Based on Positions

CBA

Org

anizatio

nCBA CHINESE

BIOSCIENCEASSOCIATION

Key Even

ts


CBA 17th Annual Conference 2014 Date/Time: October 4, 2014, 9:00 am - 5:00 pm

Venue: Crowne Plaza, Foster City, CA


Key Even

ts


2014 Ho Family Scholarship The Scholarship was presented to Miss Audrey Cheng by Mr. Caesar Ho. Miss Audrey Cheng was a 11th Grade student at Gunn High School, Palo Alto. She has a weighted GPA of 4.3. She is also the Founder, President of the American Chemistry Society Chemistry Club, Founder Captain of Science Bowl Team and the Vice President of Science Olympiad Club.

Dr. Patty Kiang, Mr. Caesar Ho, Miss Audrey Cheng and Dr. Michelle Chen. (From left to right)


Key Even

ts


Modern Seafarer: Navigating Life Sciences Investments and Entrepreneurship between

US and the Far East Date/Time: June 10, 2015, 6:00pm - 9:00pm Venue : Cooley LLP, Palo Alto CAEvent Chair: Cheni Kwok Ph.D., CLP, Managing Partner, Linear Dreams Moderator: Cheni Kwok Ph.D., CLP, Managing Partner, Linear Dreams & Glen Sato, J.D., M.B.A., Partner, Cooley

The life sciences sector reached new heights in performance in the IPO market as well as M&A in 2014. Global life sciences M&A deal value and volume surged to record high since 2000. What are the opportunities and challenges for entrepreneurs who wish to venture to the Far East? What are the investors looking for in funding new companies that operate on both sides of the Pacific Ocean? When will the trade winds change and what can we do as entrepreneurs and investors to catch them? More than 90 CBA, EPPIC, CABS, BayHelix members and friends registered for this highly anticipated event. Our modern seafarers shared their expertise and shared invaluable experience to help guide our entrepreneurs to navigate between US and the Orient.

Speakers:Anula Jayasuriya, M.D., Ph.D., M.B.A., Co-founder of Evolvence India Life Science FundCheng Liu, Ph.D., Founder & CEO, Eureka TherapeuticsJonathan Norris, J.D., Managing Director, Healthcare Practice, Silicon Valley BankMohan Uttarwar, MSCS, M.Eng., Co-Founder & CEO, INDx LifeCare, IncJimmy Wei, Ph.D., M.B.A., Venture Partner, KPCB, China

Co-hosted by Sponsored by

Supported by



Key Even

ts



Key Even

ts


Singapore-Sichuan Hi-Tech Innovation (SSCIP) Dinner Date/Time : June 25, 2015, 6:00 pm - 9:00 pmEvent Chair: Cheni Kwok Ph.D., CLP, Managing Partner, Linear Dreams

The Singapore-Sichuan Hi-Tech innovation Park (SSCIP) delegation visited the Bay Area and hosted a dinner with CBA and local companies. Mr. Chong Joon Woon, Vice President of Sembcorp Development which is a shareholder of SSCIP and an international leader in urban development led the Singapore and Chengdu delegation to engage with key companies. This event was an excellent opportunity for local companies and entrepreneurs to learn more about this exciting joint venture between Sichuan, China and Singapore. SSCIP is poised to be a biomedical sciences research and innovation hub to harness the local talent pool, a manufacturing launch pad to target the regional market, and a procurement base to contract research and collaboration services tapping the local capabilities.

Co-hosted by



Key Even

ts


CBA Summer PicnicDate/Time : August 29, 2015, 11:00 am - 2:00 pm Venue : Mitchell Park, 600 East Meadow Drive, Palo Alto, CA

A fun weekend for the families of CBA members and friends with an attendance of over 150. Good music and great food. Excellent time to catch up with old friends and network with new friends.


CBA

Histo

ry


1999 President’s MessageThe Chinese Bioscience Association started in late 90’s from a scatter of individual Chinese Bioscientists working at San Francisco Bay area. With few connections outside of our individual workplaces, many of our original members sought to socialize with other Chinese professionals in the bio-science field. Eventually, our casual socials turned increasing academic as our shared interests in bio-science compelled us to seek out more established individuals in the field to share their experiences and knowledge. With a desire to learn, therefore, our the humble group of Bio-scientists formed the beginning of CBA. Looking back now, with our fantastic annual conference and many members, it is amazing to see how much our organization has grown. As a past president, I am truly grateful that so many of you still share our passion for kinship and bioscience. I wish you all the best, and hope that you all enjoy another successful annual conference.

1998-2014 OfficersYear President Vice President Secretary Treasurer2014 Michelle Chen Patty Kiang Mark Chen Katherine Wang2013 Lin Sun-Hoffman Shih-Chen Chang Angie Wu Katherine Wang2012 Peiwen Yu Son Kuan/Andrew Teng Shwu-Hwa Lin Katherine Wang2011 Patty Kiang Li-Fen Lee Cindy Liu Katherine Wang2010 Sydney Chen Patty Kiang/Yong-Liang Zhu Tai-Kai Li Katherine Wang2009 Stella Chang Sydney Chen Tai-Kai Li Wei Chen/

Katherine Wang2008 Lichun Huang N/A N/A N/A2007 Kelly Liu/Fong-Yih Bih Cheng-Chi Chao N/A N/A2006 Betty Chang N/A N/A N/A2005 Joshua Chang Fong Yih Bih N/A N/A2004 Jer-Kang Chen N/A N/A N/A2003 Effie Lin Jer-Kang Chen N/A N/A2002 Jin-Chen Yu Effie Lin N/A N/A2001 Maureen Wang/Jin-Chen Yu Effie Lin N/A N/A2000 Maureen Wang Jin-Chen Yu N/A N/A1999 James Fann Maureen Wang N/A N/A1998 Shian Jiun Shih James Fann N/A N/A


CBA

Histo

ry


2009-2014 Publications

Monthly Newsletters


Spo

nso

rs

Our Platinum Sponsors:


Our Gold Sponsors:


Spo

nso

rs


Our Silver Sponsors:

Our Location Sponsors:


Spo

nso

rs Ad

vertisemen

ts


About AbGenomics International AbGenomics International incorporated in Delaware US, is a biopharmaceutical company integrated globally and

virtually to develop targeted therapeutics for the treatment of cancer and immune related inflammatory

diseases. AbGenomics has full capacities from managing research discovery, preclinical and clinical development,

as well as strategic planning to commercialization of its therapeutics through collaboration with alliance

partners. Numbers of highly differentiated and best-‐in-‐class drug candidates have been developed in our

company pipelines.

Our pipelines AbGenomics has built a differentiated, niche pipeline of antibody targeted therapy at various developmental

stages. Please visit our website for the details. Our most advanced program, Neihulizumab, centers as a

first-‐in-‐class antibody targeting a variety of immune-‐mediated inflammatory diseases and steroid-‐refractory

acute GvHD. The company has also developed and owned a proprietary linker-‐payload platform which

successfully overcomes major obstacles in the development of antibody-‐drug conjugate (ADC). Our

bio-‐better/bio-‐superior ADCs have demonstrated superior antitumor activity and safety profiles over our

competitors.

Partnerships and Strategic Alliances AbGenomics believes working collaboratively is a key to success in maintaining competitiveness in the Biotech

industry. AbGenomics welcomes every collaboration opportunity with academic institutions, biotech and

pharmaceutical companies worldwide in new drug discovery, development, and marketing. Career Opportunity We are constantly looking for high-‐energy, talented people who want to make a meaningful difference for our

company. Please see our website for the details.

Contact Us For more information about our products, partnership, collaboration and job opportunity, please contact:

AbGenomics International, Inc.

http://www.abgenomics.com/

e-‐mail: [email protected]


Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts



Spo

nso

rs Ad

vertisemen

ts


For a Free Real Estate/Loan Consultation, Call

Allison Y. Yang, GRI Realtor/Loan Consultant Direct : 408-390-0890 Email:[email protected] Office:408-526-0211 Fax : 650-204-6158 BRE# 01324947, NMLS# 343750 2635 N. First St. #225 San Jose, CA 95134

Real Estate: Buying, Selling, Investing & Relocation Mortgage: Purchase & Refinance

360 Merrimack St. Building 9, Lawrence, MA 01843 978-327-5340 [email protected] www.nexcelom.com

Spo

nso

rs Ad

vertisemen

ts


Spo

nso

rs Ad

vertisemen

ts



CRISPR Cell Line Model Generation

Genome Editing in vitro and in vivo

TARGATT™ Site-Speci�c Knock-in Mouse

iPSC Generation / Di�erentiation / Gene Correction

[email protected], 1-866-497-4180 (Toll Free)521 Cottonwood Dr. #111, Milpitas, CA 95035 USAwww.appliedstemcell.comAAALAC Certi�ed

Stem Cell Culture Products / Patient Samples

CRISPR Animal Model Generation

2D/3D Cell Culture MyEZGel™

Spo

nso

rs Ad

vertisemen

ts



Taiwan Innovation and Entrepreneurship Center (TIECTW) - the focal point of contact in the SF Bay Area for startups from Taiwan

What we do?

WWW.TIECTW.COMTaiwan Innovation and Entrepreneurship Center2870 Zanker Road, Suite 140, San Jose, CA 95134Tel. 408-806-5833

Con

ference N

otes



Con

ference N

otes





Documents

Chinese Bioscience Association 18 Annual Conference ... · 2 CBA Chinese Bioscience Association Shih-Chen Chang Ph.D. 2015 CBA President The Chinese Bioscience Association (CBA),